中国肛肠病杂志2026，Vol.46Issue(8)：21-25,5.
泛免疫炎症值对晚期结直肠癌患者贝伐珠单抗治疗疗效的预测价值
Predictive Value of Pan-Immune-Inflammation Value for Therapeutic Efficacy of Bevacizumab in Patients with Advanced Colorectal Cancer
摘要
Abstract
Objective To explore the predictive value of pan-immune-inflammation value(PIV)for the therapeutic efficacy of Bevacizumab in patients with advanced colorectal cancer(CRC).Methods Clinical data of 110 patients with advanced CRC admitted to our hospital from June 2020 to February 2023 were retro-spectively analyzed.Receiver operating characteristic(ROC)curve was applied to evaluate the predictive value of PIV for the therapeutic efficacy of Bevacizumab in patients with advanced CRC.According to the cut-off value,patients were divided into the low PIV group(PIV<286.45,63 cases)and the high PIV group(PIV≥286.45,47 cases).Univariate and multivariate stepwise Logistic regression analyses were performed to iden-tify the influencing factors of therapeutic effect of Bevacizumab in patients with advanced CRC,and survival analysis was performed by the Kaplan-Meier method.Results ROC analysis showed that the area under the curve(AUC)(95%CI)of PIV in predicting the therapeutic efficacy of Bevacizumab was 0.882(0.828-0.936),with a cut-off value of 286.45,specificity of 76.39%and sensitivity of 91.25%.The proportions of patients with poorly differentiated tumor and lymph node metastasis in the high PIV group were higher than those in the low PIV group(P<0.05).The objective response rate(ORR)and disease control rate(DCR)of the high PIV group were lower than those of the low PIV group(P<0.05 or P<0.001).Multivariate analysis demonstrated that poor differentiation(OR=2.208,95%CI:1.527-3.191),liver metastasis(OR=2.259,95%CI:1.557-3.279),lymph node metastasis(OR=2.330,95%CI:1.603-3.388)and PIV≥286.45(OR=2.751,95%CI:1.812-4.177)were independent risk factors influencing DCR of Bevacizumab treat-ment in patients with advanced CRC(P<0.001).Survival analysis revealed that progression-free survival(PFS)and overall survival(OS)were significantly longer in the low PIV group compared with the high PIV group(P<0.001).Conclusion High PIV is correlated with DCR and prognosis in patients with advanced CRC receiving Bevacizumab,and PIV can serve as a potential predictive biomarker.关键词
泛免疫炎症值/晚期结直肠癌/贝伐珠单抗/疗效Key words
Pan-immune-inflammation value/Advanced colorectal cancer/Bevacizumab/Therapeutic efficacy引用本文复制引用
朱红珍,邓国华,顾玉兰,丘佳明,曹薛弦,杨柳艺,刘苇,孔炯..泛免疫炎症值对晚期结直肠癌患者贝伐珠单抗治疗疗效的预测价值[J].中国肛肠病杂志,2026,46(8):21-25,5.基金项目
苏州市科技计划项目(SLT2023007) （SLT2023007）
常熟市卫生健康委员会科技计划资助性项目暨常熟市科技发展计划(医疗卫生)指导性项目(CSWS202311) （医疗卫生）
